Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group.

King K, Grazette LP, Paltoo DN, McDevitt JT, Sia SK, Barrett PM, Apple FS, Gurbel PA, Weissleder R, Leeds H, Iturriaga EJ, Rao A, Adhikari B, Desvigne-Nickens P, Galis ZS, Libby P.

JACC Basic Transl Sci. 2016 Jan-Feb;1(1-2):73-86.

2.

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.

Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees.

Circ Heart Fail. 2016 Jan;9(1). pii: e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.

3.

Pan-Cardiac Cycle Fixed Mitral Valve Opening in an LVAD Patient Presenting with Hemorrhagic Shock.

Yoon AJ, Sohn J, Grazette L, Fong MW, Bowdish ME.

Echocardiography. 2016 Apr;33(4):644-6. doi: 10.1111/echo.13150. Epub 2015 Dec 17.

PMID:
26676075
4.

Fulminant eosinophilic myocarditis following ICD implantation in a patient with undisclosed nickel allergy.

Fung E, Fong MW, Correa AJ, Yoon AJ, Grazette LP.

Int J Cardiol. 2016 Jan 15;203:1018-9. doi: 10.1016/j.ijcard.2015.11.119. Epub 2015 Nov 17. No abstract available.

PMID:
26630628
5.

Electrocardiographic patch devices and contemporary wireless cardiac monitoring.

Fung E, Järvelin MR, Doshi RN, Shinbane JS, Carlson SK, Grazette LP, Chang PM, Sangha RS, Huikuri HV, Peters NS.

Front Physiol. 2015 May 27;6:149. doi: 10.3389/fphys.2015.00149. eCollection 2015. Review.

6.

Modern day management of giant cell myocarditis.

Chaudhry MA, Correa A, Lee C, Yoon A, Grazette L, Saremi F, Fong MW.

Int J Cardiol. 2015 Jan 15;178:82-4. doi: 10.1016/j.ijcard.2014.10.131. Epub 2014 Oct 23. Review. No abstract available.

PMID:
25464225
7.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators.

Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.

8.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees.

N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.

9.

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

Samelson EJ, Miller PD, Christiansen C, Daizadeh NS, Grazette L, Anthony MS, Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP.

J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043.

10.

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators.

Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5.

11.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

12.

Treatment of ventricular tachycardia in patients with heart failure.

Fong MW, Grazette L, Cesario D, Cao M, Saxon L.

Curr Cardiol Rep. 2011 Jun;13(3):203-9. doi: 10.1007/s11886-011-0182-5. Review.

PMID:
21445560
13.

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.

J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.

PMID:
21289258
14.

Role of apoptosis in heart failure.

Grazette LP, Rosenzweig A.

Heart Fail Clin. 2005 Jul;1(2):251-61. Review. No abstract available.

PMID:
17386850
15.

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T.

Nat Med. 2006 Aug;12(8):908-16. Epub 2006 Jul 23.

PMID:
16862153
16.

C4d deposition in cardiac allografts correlates with alloantibody.

Smith RN, Brousaides N, Grazette L, Saidman S, Semigran M, Disalvo T, Madsen J, Dec GW, Perez-Atayde AR, Collins AB.

J Heart Lung Transplant. 2005 Sep;24(9):1202-10.

PMID:
16143234
17.

Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle.

Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L.

Magn Reson Med. 2005 Sep;54(3):718-24.

18.

PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury.

Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, Hemmings BA, Kass DA, Champion HC, Rosenzweig A.

J Clin Invest. 2005 Aug;115(8):2128-38. Epub 2005 Jul 7. Erratum in: J Clin Invest. 2006 Feb;116(2):548. Hemmings, Brian [corrected to Hemmings, Brian A].

19.

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.

Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, Rosenzweig A.

J Am Coll Cardiol. 2004 Dec 7;44(11):2231-8.

20.

Cardiac-specific gene expression facilitated by an enhanced myosin light chain promoter.

Boecker W, Bernecker OY, Wu JC, Zhu X, Sawa T, Grazette L, Rosenzweig A, del Monte F, Schmidt U, Hajjar RJ.

Mol Imaging. 2004 Apr;3(2):69-75.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk